Ingrid Charlotta (Lotta) Ljungqvist (General Electric (Group))

Ljungqvist, Ingrid Charlotta (Lotta) (General Electric 201709 CEO of GE Nordics)

	Product	LIFE SCIENCES

Abzena plc. (9/19/17). "Press Release: Abzena Appoints Lotta Ljungqvist as Non-Executive Director". Cambridge.

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company.

Lotta Ljungqvist has a broad range of commercial and directorial experience. She currently holds a dual role as President and CEO of GE Nordics, responsible for GE’s growth in all sectors across the region. She is also CEO of BioProcess Innovation Hub, a government initiative, where she has been setting up a new facility aiming to support biotechnology companies in Scandinavia.

Before taking on the dual role at GE Nordics she spent eight years with GE Healthcare Life Sciences as its Global Head of R&D BioProcess. During this time, the division doubled in size due to a series of acquisitions.

Prior to this, Lotta was CEO of a start-up Biotech, IMED AB, based on research from the Karolinska Institute. She also worked at Biovitrum AB for six years, as SVP, Biopharmaceutical Process Development, selling cell culture, purification and analytical services to the biopharmaceutical sector.

Lotta has held several board positions including her current position as Non-Executive Director on the board of Atlas Antibodies, a privately held manufacturer and distributor of research antibodies and as Board Director of Vinnova, the Swedish government agency that administers state funding for research and development.

Dr Ken Cunningham, Abzena’s Chairman, said:

“Lotta has a deep understanding of biomanufacturing and development services, and how to support the needs of biopharmaceutical companies. As a result of her strategic and operational capability, to manage a contract development and manufacturing service business, she will be an invaluable asset to Abzena, as it aims to deliver value-adding services and technology solutions to its customers.”

Full name: Ingrid Charlotta (“Lotta”) Ljungqvist

Age: 56 years old

Current directorships:

International General Electric Aktiebolag

North Pole Holdings AB

GECAS Sverige Aircraft Leasing Worldwide AB

GE Renewable Sweden AB

GE Energy (Sweden) AB

GE Power Sweden AB

GE Grid Solutions AB

GE Healthcare Sverige AB

GEMS PET Systems Aktiebolag

GE Healthcare Aktiebolag

GE Healthcare Life Sciences Innovation Center AB

GE Energy (Norway) AS

GE Healthcare AS

GE Healthcare AB

Atlas Antibodies AB

4L Bioconsulting AB

Antonov Thelander i Gimle Consulting Aktiebolag

GE Global Holdings Denmark ApS

Directorships in the last five years:

GE BioProcess R&D AB

Current shareholding in the Company:

Nil

Save as set out in this announcement, there are no further matters to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules for Companies.

-Ends-

Enquiries:

Abzena plc
John Burt, Chief Executive OfficerJulian Smith, Chief Financial Officer
+44 1223 903498

Numis (Nominated Adviser and Broker)
Clare Terlouw / James Black / Paul Gillam
+44 20 7260 1000

N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong
+44 20 7496 3000

Instinctif Partners
Melanie Toyne Sewell / Alex Shaw / Deborah Bell
+44 20 7457 2020
abzena@instinctif.com

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term ‘ABZENA Inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘ABZENA Inside’ products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

> Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
> Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
> Cell line development for the manufacture of recombinant proteins and antibodies;
> Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
> Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
> Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
> GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see www.abzena.com